Molina Arturo MD's Form 4 filing
Protagonist Therapeutics, Inc (PTGX) · filed Mar 27, 2026
- Accession no.
- 0001104659-26-036319
- Filed
- Mar 27, 2026
- Trade date
- Mar 26, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.57M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Molina Arturo MDCIK 0001398940 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Common Stock | MOption exerciseAcquired | +15,000 | $8.04 | +$120,600 | 99,115 | Direct | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −15,000 | $104.79F1 | −$1,571,850 | 84,115 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 50,971 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $103.99 to $105.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.